Get the Stockscreener App
10.97
6.24%
-0.73
After Hours:
11.08
0.11
+1.00%
Immix Biopharma Inc stock is traded at $10.97, with a volume of 1.83M.
It is down -6.24% in the last 24 hours and down -24.19% over the past month.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
See More
Previous Close:
$11.70
Open:
$11.78
24h Volume:
1.83M
Relative Volume:
1.05
Market Cap:
$784.79M
Revenue:
-
Net Income/Loss:
$-34.98M
P/E Ratio:
-11.93
EPS:
-0.9199
Net Cash Flow:
$-32.77M
1W Performance:
-12.24%
1M Performance:
-24.19%
6M Performance:
+23.12%
1Y Performance:
+437.75%
1-Day Range:
$10.82
$11.99
1-Week Range:
$10.82
$12.90
52-Week Range:
$1.99
$15.10
Immix Biopharma Inc Stock (IMMX) Company Profile
Name
Immix Biopharma Inc
Sector
Industry
Phone
(888) 958-1084
Address
11400 WEST OLYMPIC BLVD., LOS ANGELES
Compare IMMX vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
10.97 | 784.79M | 0 | -34.98M | -32.77M | -0.9199 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immix Biopharma Inc Stock (IMMX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-26 | Initiated | Morgan Stanley | Overweight |
| Mar-09-26 | Initiated | Citizens | Mkt Outperform |
| Feb-09-26 | Initiated | Mizuho | Outperform |
Immix Biopharma Inc Stock (IMMX) Latest News
Immix Biopharma, Inc.(NasdaqCM: IMMX) added to S&P Global BMI Index - marketscreener.com
Immix Biopharma Stock Price Forecast. Should You Buy IMMX? - StockInvest.us
Top BioTech SMidcap Stock: Mizuho Analyst Highlights IMMX By Investing.com - Investing.com South Africa
Mizuho raises Immix Biopharma stock price target to $26 on expansion By Investing.com - Investing.com South Africa
Mizuho raises Immix Biopharma stock price target to $26 on expansion - Investing.com
Mizuho Raises Price Target on Immix Biopharma to $26 From $15, Keeps Outperform Rating - Yahoo Finance
IMMX: NXC-201 shows strong efficacy and safety in AL amyloidosis, with pivotal data and BLA submission ahead - TradingView
IMMX: NXC-201 demonstrates rapid, durable responses and strong safety in AL amyloidosis, advancing toward approval - TradingView
Immix Biopharma (IMMX) Holds at $13.77: Biotech Stock Navigates Tight Trading RangeBeta Neutral Pair - dars.gov.et
IMMX Q2 2026 Earnings: Modest EPS Miss Signals Continued Clinical-Stage InvestmentPre-Earnings Drift - careplusvn.com
Immix (IMMX) Today: Moves 1.32% Lower to $13.48 at the Close; Chart Watch: the Price Remains Bounded by the Supplied Support and Resistance in the Available RecordUp Down Volume - vinanet.vn
Immix (IMMX) Latest: Ends Higher by 3.80% at $13.66 in Latest Trading; Technical View: the Price Remains Bounded by the Supplied Support and Resistance in Latest TradingScalping Stock Signals - dars.gov.et
Tocqueville Asset Management L.P. Buys New Position in Immix Biopharma, Inc. $IMMX - MarketBeat
Blue Owl Capital Holdings LP Makes New $4.51 Million Investment in Immix Biopharma, Inc. $IMMX - MarketBeat
Immix (IMMX) Quarterly Scorecard: The Available Figures Are Largely in Line on the Day; Session Move: Shares Fall 1.21% in the Current UpdatePre-Earnings Setup - vinanet.vn
Immix Biopharma (NASDAQ:IMMX) Sets New 12-Month HighStill a Buy? - MarketBeat
Analysts Offer Insights on Healthcare Companies: AEON Biopharma (AEON) and Immix Biopharma (IMMX) - The Globe and Mail
Immix Biopharma (NASDAQ:IMMX) Stock Price Down 4.5%Here's Why - MarketBeat
Immix Biopharma (IMMX) gains 5.6% stake holder led by Eventide Asset Management - Stock Titan
Citizens reiterates Immix Biopharma stock rating on pipeline progress By Investing.com - Investing.com Australia
Citizens reiterates Immix Biopharma stock rating on pipeline progress - Investing.com
Janus Henderson Group (IMMX) discloses 9.78M-share beneficial stake in Immix Biopharma - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc.IMMX - PR Newswire
Immix Biopharma Q3 EPS Estimate Lowered by HC Wainwright - MarketBeat
Immix Biopharma (NASDAQ:IMMX) Trading 7.1% HigherStill a Buy? - MarketBeat
HC Wainwright Estimates Immix Biopharma FY2027 Earnings - MarketBeat
Immix Biopharma publishes corporate presentation on NXC-201 BCMA CAR-T in relapsed/refractory AL amyloidosis - Bitget
Immix Biopharma, Inc. Stock 12‑Month Price Target Cut to $20.44, Implies 102% Upside - TradingView
Morgan Stanley Adjusts PT on Immix Biopharma to $19 From $20, Maintains Overweight Rating - marketscreener.com
IMMIX BIOPHARMA, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $25 FROM $20 - Bitget
H.C. Wainwright raises Immix Biopharma price target to $25 By Investing.com - Investing.com Australia
H.C. Wainwright raises Immix Biopharma price target to $25 - Investing.com India
Regulatory and Data Risks Loom Over Immix Biopharma’s Clinical Programs and Valuation - TipRanks
IMMX Q1 2026 Earnings: Narrower-Than-Expected Loss of $0.18 per Share, Shares Dip 3.38%Analyst Drop Coverage - careplusvn.com
Immix Biopharma (NASDAQ:IMMX) Announces Quarterly Earnings Results - MarketBeat
Immix Biopharma (NASDAQ: IMMX) ends Q2 2026 with $232.1M in cash - Stock Titan
Immix Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Immix Biopharma (NASDAQ:IMMX) Stock Price Down 6.7%Here's What Happened - MarketBeat
Immix Biopharma Inc (IMMX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
IMMX Q1 2026 Earnings: 15.25% EPS Surprise on Narrower Loss Despite No RevenueProfit Warning Alert - vinanet.vn
Immix Biopharma (IMMX) Projected to Post Quarterly Earnings on Friday - MarketBeat
IMMX Investors Have Opportunity to Join Immix Biopharma, Inc. Fraud Investigation with SBS Law - Business Wire
Immix Biopharma, Inc. (NASDAQ:IMMX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Immix Biopharma (IMMX) Advances 5.45% as Biotech Sentiment StrengthensBullish Sentiment - dars.gov.et
Immix Biopharma faces investigation after hirin... - Pluang
Immix Biopharma, Inc. expected to post a loss of 18 cents a shareEarnings Preview - TradingView
Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - Investing News Network
ImmixBio plans one-on-one investor meetings in New York Sept. 14-16 - Stock Titan
Immix Biopharma Inc Stock (IMMX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):